Phase 2 Borderline Resectable Pancreatic Adenocarcinoma Clinical Trials
6 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–6 of 6 trials
Recruiting
Phase 2
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Pancreas AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences64 enrolled1 locationNCT05825066
Recruiting
Phase 2
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang University40 enrolled2 locationsNCT07240766
Recruiting
Phase 1Phase 2
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic AdenocarcinomaLocalized Pancreatic Adenocarcinoma
Amsterdam UMC, location VUmc66 enrolled4 locationsNCT06384560
Recruiting
Phase 1Phase 2
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center56 enrolled1 locationNCT05688215
Recruiting
Phase 2
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Pancreatic AdenocarcinomaPancreatic NeoplasmBorderline Resectable Pancreatic Adenocarcinoma
Erasme University Hospital256 enrolled10 locationsNCT05083247
Completed
Phase 2
A study looking at the use of Mfolfirinox Chemotherapy And Stereotactic Radiotherapy for Patients with Locally Advanced pancreatic cancer to evaluate if this is a feasible treatment option with acceptable acute toxicity rates.
Unresectable Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Liverpool Hospital10 enrolled3 locationsACTRN12617001642370